LISATA THERAPEUTICS, INC. — Director's Dealing 2018

Jun 21, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CALADRIUS BIOSCIENCES, INC. (CLBS)
CIK: 0000320017
Period of Report: 2018-06-20

Reporting Person: Mazzo David J (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-06-20	Common Stock	A	33300	$8.64	Acquired	125544	Direct
2018-06-20	Common Stock	F	16091	$8.64	Disposed	109453	Direct

Footnotes

F1: Reflects 33,300 in performance rights, the criteria for which was satisfied on April 6, 2018 and which vested in full on June 20, 2018, when the shareholders voted to approve the new 2018 Equity Incentive Compensation Plan.

F2: Includes 24,975 shares of unvested restricted stock.